loading
Pmv Pharmaceuticals Inc stock is traded at $1.24, with a volume of 40,837. It is down -1.59% in the last 24 hours and down -12.68% over the past month. PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$1.26
Open:
$1.2535
24h Volume:
40,837
Relative Volume:
0.25
Market Cap:
$64.40M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.24
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
+0.81%
1M Performance:
-12.68%
6M Performance:
-17.88%
1Y Performance:
-22.50%
1-Day Range:
Value
$1.23
$1.27
1-Week Range:
Value
$1.20
$1.2788
52-Week Range:
Value
$1.20
$2.26

Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile

Name
Name
Pmv Pharmaceuticals Inc
Name
Phone
(609) 642-6664
Name
Address
ONE RESEARCH WAY, PRINCETON
Name
Employee
47
Name
Twitter
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
PMVP's Discussions on Twitter

Compare PMVP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PMVP
Pmv Pharmaceuticals Inc
1.24 64.40M 0 -51.47M -47.50M -1.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-08-24 Upgrade Oppenheimer Perform → Outperform
May-13-24 Initiated Craig Hallum Buy
Apr-12-24 Initiated Jefferies Buy
Dec-27-23 Initiated Ladenburg Thalmann Buy
Mar-02-22 Upgrade Oppenheimer Perform → Outperform
Sep-22-21 Upgrade Goldman Neutral → Buy
Aug-19-21 Initiated Oppenheimer Perform
Aug-02-21 Initiated Guggenheim Buy
Jul-29-21 Initiated H.C. Wainwright Buy
Oct-20-20 Initiated BofA Securities Buy
Oct-20-20 Initiated Cowen Outperform
Oct-20-20 Initiated Evercore ISI Outperform
Oct-20-20 Initiated Goldman Neutral
View All

Pmv Pharmaceuticals Inc Stock (PMVP) Latest News

pulisher
Mar 12, 2025

PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 05, 2025

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Zacks Investment Research

Mar 05, 2025
pulisher
Mar 03, 2025

PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

PMV Pharmaceuticals stock hits 52-week low at $1.32 - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire

Mar 03, 2025
pulisher
Feb 27, 2025

PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

3 US Penny Stocks To Consider In February 2025 - Simply Wall St

Feb 26, 2025
pulisher
Feb 24, 2025

PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0

Feb 24, 2025
pulisher
Feb 20, 2025

PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily

Feb 20, 2025
pulisher
Feb 20, 2025

Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace

Feb 20, 2025
pulisher
Feb 19, 2025

Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz

Feb 19, 2025
pulisher
Feb 18, 2025

Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire

Feb 18, 2025
pulisher
Feb 14, 2025

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat

Feb 14, 2025
pulisher
Feb 12, 2025

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com

Feb 12, 2025
pulisher
Feb 11, 2025

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

PMVP's Top Executives Set to Reveal Latest Oncology Developments at Major Healthcare Conferences - StockTitan

Feb 11, 2025
pulisher
Jan 28, 2025

US Penny Stocks To Watch In January 2025 - Simply Wall St

Jan 28, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Reduces Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Jan 26, 2025
pulisher
Jan 25, 2025

Barclays PLC Trims Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat

Jan 25, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Sells 18,128 Shares of New Found Gold Corp. (NYSE:NFGC) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 10, 2025

Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Jan 10, 2025
pulisher
Jan 10, 2025

Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat

Jan 10, 2025
pulisher
Jan 08, 2025

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer - The Manila Times

Jan 08, 2025
pulisher
Jan 07, 2025

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire

Jan 07, 2025
pulisher
Jan 02, 2025

Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech

Jan 02, 2025
pulisher
Dec 30, 2024

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial - Nature.com

Dec 30, 2024
pulisher
Dec 20, 2024

Institutional investors may overlook Premier Investments Limited's (ASX:PMV) recent AU$278m market cap drop as long-term gains remain positive - Yahoo Finance

Dec 20, 2024
pulisher
Dec 06, 2024

When Should You Buy Premier Investments Limited (ASX:PMV)? - Yahoo Finance

Dec 06, 2024
pulisher
Dec 03, 2024

Discover 3 US Penny Stocks With Market Caps Over $40M - Simply Wall St

Dec 03, 2024
pulisher
Dec 03, 2024

ArrowMark Colorado Holdings LLC Purchases 842,509 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat

Dec 03, 2024
pulisher
Dec 03, 2024

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Given Average Rating of "Buy" by Brokerages - MarketBeat

Dec 03, 2024
pulisher
Nov 29, 2024

Sio Capital Management LLC Boosts Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

PMVP (PMV Pharmaceuticals) 6-Month Price Index : 0.78 (As of Nov. 28, 2024) - GuruFocus.com

Nov 28, 2024
pulisher
Nov 20, 2024

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Sionna Therapeutics Appoints Laurie Stelzer to its Board of Directors - citybiz

Nov 18, 2024

Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mack David Henry
President and CEO
Jan 03 '25
Option Exercise
0.53
17,709
9,386
551,919
Jalota Deepika
Chief Development Officer
Sep 11 '24
Sale
1.50
7,218
10,853
118,283
Carulli Michael
Chief Financial Officer
Sep 11 '24
Sale
1.50
2,891
4,347
88,395
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):